Merck Invests In China Oncology Start-Ip BeiGene
Executive Summary
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
You may also be interested in...
Start-Up Quarterly Statistics, Q2 2011
Funding for biopharma start-ups nearly doubled from Q1 to Q2 2011, with a total of $251 million. The quarter saw increased investment in emerging markets, particularly in China. Biopharma start-ups scored many deals with Big Pharma, in several cases playing the role of licensee. And while M&A activity for the start-up set was limited to two deals, for each of those agreements the start-ups were the ones on the acquiring side scooping up assets from other companies.
ASLAN Completes Series A Funding For $12 Mn; Eyes More Financing Options With Spiraling Portfolio
MUMBAI - Singapore-based discovery research start-up ASLAN Pharmaceuticals reached a major milestone as it completed its Series A financing of $12 million. The fund will be utilized to develop the first set of in-licensed compounds by ASLAN
Is China A Black Swan For Big Pharma? (Part 2 of 2)
[Editor's note: This is part two of a two part story; part one appeared in PharmAsia News, April 25, 2010.]